Type 2 diabetic (T2D) wounds are characterised by excessive, persistent inflammation and oxidative stress, resulting in delayed healing. The tocotrienol-rich fraction (TRF) has potential as a therapeutic agent in improving diabetic wounds due to its anti-inflammatory and antioxidative effects. Thus, we aimed to evaluate the effect of the TRF on diabetic cutaneous wounds using a T2D mouse model. Full-thickness wounds were made on the backs of mice, and the TRF formulation was topically applied. The effect of the TRF was evaluated by examining wound closure, histology, CD31 immunohistochemistry and collagen deposition with Masson’s trichrome staining. Biochemical assessments of catalase (CAT), glutathione peroxidase (GPx), myeloperoxidase (MPO), protein levels, transforming growth factor beta-1 (TGF-β1), metalloproteinase-9 (MMP-9) and cytokine production were performed. The results showed that TRF treatment enhanced wound closure and healing in the T2D mouse wounds. The TRF increased CAT, GPx, protein, hydroxyproline and TGF-β1 levels but reduced MPO activity and MMP-9 production in diabetic wounds. Multiplex immunoassay revealed that the TRF modulated proinflammatory cytokine and chemokine production. However, it increased interleukin-4 (IL-4) and vascular endothelial growth factor (VEGF) production and reduced granulocyte-macrophage colony-stimulating factor (GM-CSF). Our data suggest that topical TRF application may enhance diabetic cutaneous wound healing.